CLSD实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (22 May 2024 @ 04:00):

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space...

Stats
今日成交量	896 190
平均成交量	381 361
市值	111.35M
EPS	$0 ( 2024-05-09 )
下一个收益日期	( $-0.140 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.71
ATR14	$0.0220 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Yerxa Benjamin R	Buy	7 813	Common Stock
2024-04-18	Gibney Anthony S	Buy	93 290	Common Stock
2024-04-17	Gibney Anthony S	Buy	6 710	Common Stock
2024-04-15	Gibney Anthony S	Buy	45 000	Stock Option (right to buy)
2024-04-15	Gibney Anthony S	Buy	0

INSIDER POWER
67.80
Last 97 transactions
Buy: 5 503 181 \| Sell: 2 142 358

音量相关性

長: -0.30 (neutral)

短: 0.35 (neutral)

Signal:(65.169) Neutral

Clearside Biomedical Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Clearside Biomedical Inc 相关性 - 货币/商品

-0.28
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.00
( neutral )

0.35
( neutral )

Clearside Biomedical Inc 财务报表

Annual	2023
营收:	$8.23M
毛利润:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2023
营收:	$8.23M
毛利润:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2022
营收:	$1.33M
毛利润:	$1.12M (84.63 %)
EPS:	$-0.570

FY	2021
营收:	$29.58M
毛利润:	$29.58M (100.00 %)
EPS:	$0.00632

Financial Reports:

No articles found.

Clearside Biomedical Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.